NASDAQ$ICUI

ICU Medical Inc. · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

Announced fourth quarter 2020 results.

ICU Medical, Inc. reported fourth quarter revenue of $320.5 million, compared to $315.5 million in the same period last year. GAAP net income for the fourth quarter of 2020 was $26.1 million, or $1.21 per diluted share, as compared to GAAP net income of $20.6 million, or $0.96 per diluted share, for the fourth quarter of 2019.

  • Fourth quarter 2020 revenue was $320.5 million, compared to $315.5 million in the same period last year.
  • GAAP gross profit for the fourth quarter of 2020 was $119.9 million, as compared to $114.1 million in the same period last year.
  • GAAP net income for the fourth quarter of 2020 was $26.1 million, or $1.21 per diluted share
  • Adjusted diluted earnings per share for the fourth quarter of 2020 were $1.77 as compared to $1.94 for the fourth quarter of 2019.

Headline financials

Total Revenue

$320M

Previous: $316M+1.6%
EPS (adj)

$1.77

Previous: $1.94-8.8%
Adjusted EBITDA

$59.8M

Previous: $60.7M-1.5%
GAAP Gross Margin

37.0%

Previous: 36.0%+2.8%
Capital Expenditures

$29.6M

Previous: $24.1M+23.2%
Free Cash Flow

$48.9M

Previous: $24.8M+97.1%
Net Income

$26.1M

Previous: $20.6M+26.7%
Operating Income

$27M

Previous: $17.8M+51.6%
Gross Profit

$120M

Previous: $114M+5.0%
Cash & Equivalents

$396M

Previous: $269M+47.4%
Total Assets

$1.76B

Previous: $1.69B+4.2%
Stock-Based Comp

$5.34M

Previous: $5.76M-7.2%

Revenue & EPS history

ICU Medical · Revenue · Quarterly

$320M

Q4 2020+1.6%vs Q4 2019
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

ICU Medical · $215M total across 2 segments · Q4 2020

  • Consumables
    $123M+2.9%
  • Infusion Systems
    $91.8M+9.5%

Forward guidance

For the Fiscal Year 2021, the Company expects adjusted EBITDA to be in the range of $245 million to $265 million, and adjusted diluted EPS to be in the range of $6.50 to $7.20.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

+0.3%

Avg return

Earnings day

-1.1%

Avg return

5 days after

-0.3%

Avg return

30 days after

52%

38 / 73 earnings

Positive

+22.4%

Q2 2024

Best reaction

-33.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.8%-0.8%+10.7%
Q4 2025+4.8%+3.6%-16.3%
Q3 2025+8.2%+7.3%+9.9%
Q1 2025-3.3%-4.9%-6.9%
Q4 2024-2.3%-4.1%-6.4%
Q3 2024-1.9%-5.8%-7.1%
Q2 2024+22.4%+19.7%+31.2%
Q1 2024-0.1%+6.3%+7.6%
Q4 2023+6.5%-0.2%+1.6%
Q3 2023-17.8%-20.2%-15.9%
Q2 2023-15.2%-15.6%-16.8%
Q1 2023+13.3%+8.7%+3.9%
Q4 2022-3.6%-4.2%-7.3%
Q3 2022+6.7%+21.4%+11.8%
Q2 2022-7.4%-4.7%-8.0%
Q1 2022-10.4%-15.0%-14.9%
Q4 2021+5.8%+9.0%+4.3%
Q3 2021+2.1%+2.7%-6.4%
Q2 2021+0.7%+1.2%+6.1%
Q1 2021-5.0%-6.5%-2.1%
Q4 2020-5.5%-6.8%-4.4%
Q3 2020+0.6%+4.8%+5.6%
Q2 2020+8.8%+5.0%+9.8%
Q1 2020-8.8%-13.7%-8.0%
Q4 2019-4.2%-4.8%-8.2%
Q3 2019+6.9%+4.3%+6.8%
Q2 2019-33.3%-31.2%-36.6%
Q1 2019-2.7%-3.3%-2.2%
Q4 2018+2.5%-4.9%-2.8%
Q3 2018-10.6%-14.8%-10.6%
Q2 2018+2.2%+2.4%+3.7%
Q1 2018+1.4%+4.3%+12.4%
Q4 2017+4.6%+7.5%+9.1%
Q3 2017+8.6%+10.1%+11.7%
Q2 2017-2.9%-2.4%+3.4%
Q1 2017-0.2%-0.1%+6.2%
Q4 2016+0.7%-1.0%+1.5%
Q3 2016-0.4%-0.9%+2.5%
Q2 2016+7.5%+6.1%+8.6%
Q1 2016-1.0%
Q4 2015-8.7%
Q3 2015+5.8%
Q2 2015+19.9%
Q1 2015+7.3%
Q4 2014+2.2%
Q3 2014+13.6%
Q2 2014+10.5%
Q1 2014+3.3%
Q4 2013+0.1%
Q3 2013+3.0%
Q2 2013-6.7%
Q1 2013+1.3%
Q4 2012+1.1%
Q3 2012+3.7%
Q2 2012-0.2%
Q1 2012+0.8%
Q4 2011+1.9%
Q3 2011+0.2%
Q2 2011-3.9%
Q1 2011+2.2%
Q4 2010+0.1%
Q3 2010-0.9%
Q2 2010+3.4%
Q1 2010-1.0%
Q4 2007-1.0%
Q4 2009-1.0%
Q3 2009-0.8%
Q3 2008-0.8%
Q2 2009-0.6%
Q2 2008-3.9%
Q1 2009-3.9%
Q4 2008-3.9%
Q1 2008-3.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro